332.29999 EUR
0.6
0.18%
Last update Dec 16, 9:55 PM CET
Market closed
Day range
330
332.70001
Previous close
332.89999
Open
330
Access this stock data via API
Subscribe
Alnylam Pharmaceuticals Inc.
332.30
0.60
0.18%

Financials

Income statement

Fundamentals currency is USD
Fiscal date Sep 2025 Jun 2025 Mar 2025 Dec 2024
Total reported revenue 1.1B 659.4M 506.4M 505.5M
Cost of revenue 170.6M 121.8M 60.5M 87.6M
Gross profit 893.9M 537.5M 445.9M 417.9M
Operating expense
Research & development 305.8M 275.8M 226.0M 255.8M
Selling general and admin 274.5M 275.5M 204.5M 251.7M
Other operating expenses
Operating income 313.6M -13.8M 15.4M -89.6M
Non operating interest income
Income 24.4M 23.4M 24.4M 26.4M
Expense 37.8M 34.3M 32.9M 33.2M
Other income expense -96.6M -5.5M -42.4M -68.9M
Pretax income 203.7M -30.1M -35.5M -165.3M
Tax provision -10.3M 26.4M 13.5M -93.9M
Net income 214.0M -56.5M -49.0M -71.4M
Basic EPS -0.5 -0.4
Diluted EPS -0.5 -0.4
Basic average shares 111.3M 110.5M
Diluted average shares 111.3M 110.5M
EBITDA 341.7M 30.2M 60.8M -72.1M
Net income from continuing op. 214.0M -56.5M -49.0M -71.4M
Minority interests
Preferred stock dividends
Access the full /income_statement historical dataset via the API — starting from the Pro plan.
Market closed

Exchange is currently closed
Main market opens in 4 hours 15 minutes

03:44
00:00
08:00
22:00
23:59

Trading Hours (Monday - Friday):

Main market
08:00 - 22:00
All times are displayed in the Europe/Berlin timezone (CET, UTC+01:00).